NCT06989697

Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes

Impact of Cilostazol and Ginkgo Leaf Extract on Cognitive Function in Elderly Patients With Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.

Conditions

• Type 2 Diabets Mellitus
• Cognitive Ability, General

Interventions

Type	Name	Description
DRUG	Cilostazol / Ginko Leaf Dried Ext.	Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
DRUG	Placebo	Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-12-31
• Completion: 2027-06-30
• First posted: 2025-05-25
• Last updated: 2025-05-25

Locations

1 site across 1 country: South Korea